Navigation Links
Nucletron Increases Full Year Outlook After Strong First Half 2009
Date:9/3/2009

VEENENDAAL, the Netherlands, September 3 /PRNewswire/ --

- Despite Challenging Global Economic Conditions, Nucletron Surpassed Projections for the First Half Year

Nucletron, a global leader in radiation oncology, today announced strong financial results over the first half year of 2009. Despite challenging global economic conditions, Nucletron surpassed projections for the first half year.

Net sales amounted to EUR 51.2 million, a 3% growth on like-for-like basis compared to the first half of 2008. EBITDA in the first half of 2009 amounted to EUR 6.3 million, a 53% increase compared to EUR 4.1 million over the same period last year. As a result of the positive developments Nucletron expects full year EBITDA to increase to EUR 19.0 million.

Jos Lamers, chief executive officer of Nucletron, comments: "Over the first six months of 2009, we have seen the results of our improved focus on innovation and our increased marketing efforts. Our senior management team is at full strength after the appointment of three new team members with a blue chip background. Combining our strength in marketing and sales with the research & development capabilities of Isodose Control will make Nucletron one of the global leaders in brachytherapy. Given our many upcoming product releases in the months ahead, we are on track to outperform our 2009 goals."

Among the several advancements made in the first half of 2009, Nucletron partnered with Advanced Radiation Therapy (ART) to offer a revolutionary solution for treating breast cancer. AccuBoost allows clinicians to use image-guidance, as used in a standard mammography, to pinpoint radiation directly to the tumour site. This allows for much better accuracy in targeting the radiation to the cancerous area, while protecting the patients' healthy organs during treatment.

The business collaboration with Isodose Control is now in place. The partnership allows clinicians to benefit from Nucletron's leadership and strength in brachytherapy with Isodose Control's track record of innovation.

Additionally, Nucletron launched its latest evolution in treatment planning for radiotherapy. Model-based segmentation in Oncentra MBS and volumetric modulated arc therapy with Oncentra VMAT ensure quality, while dramatically reducing the time needed to create treatment plans.

Visit our website http://www.nucletron.com

About Nucletron

Nucletron is a global leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians.


'/>"/>
SOURCE Nucletron B V
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
2. Nucletron and Advanced Radiation Therapy (ART) Jointly Announce a Global, Strategic Partnership to Offer AccuBoost(R) for Image-Guided Breast Irradiation
3. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
4. Fat on chest and upper back increases risk of insulin resistance
5. Handling Stress Properly Increases Good Cholesterol
6. High alcohol consumption increases stroke risk among Chinese men
7. High alcohol consumption increases stroke risk, Tulane study says
8. Genetic predisposition increases childhood asthma risk
9. Smoking increases risks for head and neck cancers for men and women
10. Passive smoking increases sleep disturbance among pregnant women
11. Frequent alcohol consumption increases cancer risk in older women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... The new knee ... individual looking to buy neoprene knee sleeves for lifting and any sport ... focuses heavily on two main aspects to provide a higher quality knee sleeve performance. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/4/2016)... ... December 02, 2016 , ... Metabolic Code (MC) and Power2Practice ... help doctors more efficiently manage their practice. Power2Practice is adding MC’s nutraceutical ... Integrative and Functional Medicine. , The Metabolic Code platform provides a leading-edge ...
(Date:12/4/2016)... ... ... While James Earl Jones is known for myriad roles on stage and screen, he ... of the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. ... early detection. Like any other disease, treatments have a much higher chance of success ...
(Date:12/4/2016)... ... December 04, 2016 , ... ... new attractive animation styles with unique displacement design elements," said Christina Austin - ... third designs. Choose from a variety of design styles that include both left ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... to its previously-announced cash tender offers (the "Offers") ... below (collectively, the "Notes"), approximately $2.6 billion in aggregate ... not validly withdrawn on or prior to 5:00 p.m., ... today, December 5, 2016 (the "Early Tender Deadline"). ...
(Date:12/5/2016)... , Dec. 5, 2016 France Glaucoma Surgery ... new report, "France Glaucoma Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Canaloplasty Micro Catheters and ... shares and distribution shares data for each of these ...
(Date:12/5/2016)... , Dec. 5, 2016   Mallinckrodt Pharmaceuticals ... specialty pharmaceutical company, today announced that it received a ... Equality Index (CEI), a national benchmarking survey and report ... bisexual and transgender (LGBT) workplace equality, administered by the ... of 517 major U.S. businesses which also earned top ...
Breaking Medicine Technology: